Market News

Shareholder Griffin Asset Management Has Lifted Pfizer (PFE) Holding; Gilead Sciences (GILD) Shareholder Greenwood Capital Associates Has Trimmed Stake by $628,989

Pfizer Inc. (NYSE:PFE) Logo

Griffin Asset Management Inc increased its stake in Pfizer (PFE) by 55.35% based on its latest 2017Q4 regulatory filing with the SEC. Griffin Asset Management Inc bought 31,210 shares as the company’s stock declined 3.13% with the market. The institutional investor held 87,601 shares of the health care company at the end of 2017Q4, valued at $3.17 million, up from 56,391 at the end of the previous reported quarter. Griffin Asset Management Inc who had been investing in Pfizer for a number of months, seems to be bullish on the $217.90 billion market cap company. The stock increased 0.27% or $0.1 during the last trading session, reaching $36.63. About 21.23 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 2.43% since April 23, 2017 and is uptrending. It has underperformed by 9.12% the S&P500.

Greenwood Capital Associates Llc decreased its stake in Gilead Sciences Inc (GILD) by 11.04% based on its latest 2017Q4 regulatory filing with the SEC. Greenwood Capital Associates Llc sold 8,859 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 71,350 shares of the health care company at the end of 2017Q4, valued at $5.11 million, down from 80,209 at the end of the previous reported quarter. Greenwood Capital Associates Llc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $96.09 billion market cap company. The stock decreased 0.99% or $0.74 during the last trading session, reaching $73.7. About 4.23 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 23, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Since January 2, 2018, it had 0 insider buys, and 18 sales for $39.95 million activity. 5,833 shares were sold by Cogan John Francis, worth $472,065 on Monday, March 12. Meyers James R also sold $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, January 16. 50,000 shares valued at $3.66 million were sold by MARTIN JOHN C on Monday, April 2. Washington Robin L also sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 21. WILSON GAYLE E also sold $4.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, February 9.

Greenwood Capital Associates Llc, which manages about $970.61 million and $429.27M US Long portfolio, upped its stake in Bp Plc (NYSE:BP) by 37,382 shares to 113,773 shares, valued at $4.78 million in 2017Q4, according to the filing. It also increased its holding in Ishares Msci (INDA) by 33,475 shares in the quarter, for a total of 49,532 shares, and has risen its stake in Oracle Corp (NYSE:ORCL).

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Equal-Weight” rating given on Friday, October 2 by Morgan Stanley. As per Friday, April 29, the company rating was maintained by UBS. Piper Jaffray maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, July 24. Piper Jaffray has “Overweight” rating and $131 target. William Blair maintained the shares of GILD in report on Wednesday, June 14 with “Buy” rating. Barclays Capital maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, March 6 with “Overweight” rating. The firm has “Outperform” rating by Wells Fargo given on Tuesday, January 16. The firm has “Buy” rating by Robert W. Baird given on Friday, September 15. The firm has “Buy” rating by Cowen & Co given on Monday, September 21. Jefferies maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, October 4. Jefferies has “Hold” rating and $93 target. The firm earned “Hold” rating on Wednesday, September 9 by Jefferies.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1 after the close. They expect $1.59 EPS, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.07 billion for 11.59 P/E if the $1.59 EPS becomes a reality. After $1.60 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It is negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Advisory Research reported 0% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Signaturefd Ltd Liability Corporation accumulated 5,790 shares. The California-based Brandes Invest Partners LP has invested 0.1% in Gilead Sciences, Inc. (NASDAQ:GILD). Ally Financial Incorporated holds 0.97% or 70,000 shares in its portfolio. New Jersey Better Educational Savings Trust holds 0.51% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 7,000 shares. Quantitative Systematic Strategies Ltd Liability Corp accumulated 0.12% or 6,350 shares. Stralem & stated it has 0.15% in Gilead Sciences, Inc. (NASDAQ:GILD). Quadrant Capital Mgmt Ltd has invested 1.01% in Gilead Sciences, Inc. (NASDAQ:GILD). Acropolis Invest Management Limited Com invested in 2,615 shares. Centurylink Investment Company holds 18,962 shares. Toronto Dominion Fincl Bank reported 651,482 shares stake. Convergence Investment Ptnrs Lc holds 0.9% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 94,058 shares. Foundry Prtnrs Limited Liability Com has invested 0.01% in Gilead Sciences, Inc. (NASDAQ:GILD). Grandfield & Dodd Ltd Limited Liability Company reported 135,968 shares. Rmb Capital Mngmt Ltd Liability Corp has invested 0.09% in Gilead Sciences, Inc. (NASDAQ:GILD).

Investors sentiment increased to 1.06 in 2017 Q4. Its up 0.10, from 0.96 in 2017Q3. It increased, as 51 investors sold PFE shares while 675 reduced holdings. 134 funds opened positions while 632 raised stakes. 4.07 billion shares or 0.28% more from 4.06 billion shares in 2017Q3 were reported. Brookfield Asset Mgmt Inc owns 190,125 shares. New Mexico Educational Retirement Board holds 0.79% of its portfolio in Pfizer Inc. (NYSE:PFE) for 573,650 shares. Retirement Sys Of Alabama reported 3.56M shares. 24,572 were reported by Mercer Capital Advisers Inc. The Illinois-based Bruce And Company has invested 3.57% in Pfizer Inc. (NYSE:PFE). Brinker Capital has invested 0.44% of its portfolio in Pfizer Inc. (NYSE:PFE). Thornburg Mngmt invested in 0.7% or 2.79 million shares. Community & Inv Communications reported 1.08% in Pfizer Inc. (NYSE:PFE). The Japan-based Sumitomo Mitsui Trust Holdings has invested 0.85% in Pfizer Inc. (NYSE:PFE). Modera Wealth Mngmt Limited Liability Company invested in 24,760 shares or 0.19% of the stock. Tiverton Asset Mgmt Limited Liability Co owns 0.21% invested in Pfizer Inc. (NYSE:PFE) for 93,437 shares. Vanguard Gp holds 0.69% or 433.01M shares. Balyasny Asset Mngmt Limited Company has 318,974 shares. Loomis Sayles And Limited Partnership owns 0.13% invested in Pfizer Inc. (NYSE:PFE) for 1.79M shares. Gabelli Funds Ltd Limited Liability Company owns 1.06 million shares for 0.22% of their portfolio.

Among 22 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 12 Hold. Therefore 41% are positive. Pfizer had 78 analyst reports since July 29, 2015 according to SRatingsIntel. BMO Capital Markets downgraded the stock to “Market Perform” rating in Wednesday, November 2 report. The firm earned “Neutral” rating on Monday, April 18 by Goldman Sachs. The stock of Pfizer Inc. (NYSE:PFE) earned “Overweight” rating by Piper Jaffray on Friday, August 28. The firm has “Buy” rating given on Wednesday, November 1 by UBS. On Tuesday, September 5 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Cowen & Co on Monday, July 10. The stock of Pfizer Inc. (NYSE:PFE) earned “Neutral” rating by SunTrust on Wednesday, November 25. Morgan Stanley maintained it with “Neutral” rating and $38 target in Friday, April 7 report. Credit Suisse downgraded Pfizer Inc. (NYSE:PFE) on Thursday, July 20 to “Neutral” rating. SunTrust maintained the shares of PFE in report on Monday, October 16 with “Hold” rating.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *